On March 23, 2026, Valneva SE announced that its Lyme disease vaccine LB6V showed over 70% efficacy in clinical trials, with specific efficacy rates of 73.2% and 74.8% compared to the placebo. The results indicate potential for regulatory submissions, despite fewer than expected Lyme cases during the trial.